Search the Newsreel

Solventum Corp stock hits 52-week high at 89.35 USD By Investing.com

Solventum Corp (NYSE: SOLV) stock reached a 52-week high of $89.35, trading near its peak with a market capitalization of $15.15 billion and an attractive P/E ratio of 9.3. The company has seen a 21.57% increase in stock value over the past year, reflecting …

Solventum Announces Intent to Separate its Health Information Systems Business

Solventum (NYSE: SOLV) announced its intent to separate its Health Information Systems business to optimize its portfolio and strengthen its focus as a dedicated MedTech company. This strategic move aims to unlock shareholder value, accelerate innovation, and allow both entities to pursue distinct growth …

What Solventum (SOLV)'s Earnings Beat And Health IT Spinoff Plan Means For Shareholders

Solventum supera estimaciones y eleva previsiones por sólido crecimiento

Solvonis Therapeutics Advances SVN-015 Into Further NIDA-Funded Studies Following Encouraging Initial Screening

Solventum (NYSE: SOLV) to separate $1.4B Health Information Systems arm

Solventum (NYSE: SOLV) announced its intention to separate its Health Information Systems (HIS) business, which generated $1.4 billion in net sales in 2025. This move is part of a broader portfolio optimization strategy to transform Solventum into a more focused MedTech company. The company …

Activist pressure pushes Eagan-based Solventum to divest billion-dollar business

Eagan-based Solventum, a 3M spinoff, plans to divest its Health Information Systems (HIS) unit, which generates $1.4 billion in annual sales. This move comes after sustained pressure from activist investor Trian Fund Management, one of Solventum's largest shareholders, to streamline the company's focus. The …

Solventum beats estimates, raises guidance on strong growth

Solventum Corp (NYSE:SOLV) exceeded analyst expectations in its second-quarter results and raised its full-year guidance, driven by strong organic sales growth across all business segments. The medical technology company posted adjusted EPS of $2.55, beating estimates by $1.04, and reported revenue of $2.2 billion. …

Solventum Q2 2026 Earnings: 9.5% Organic Growth Supports Higher Guidance

Solventum reported strong Q2 2026 results with 9.5% organic sales growth and a 50.9% increase in adjusted diluted EPS, prompting the company to raise its full-year guidance. While all segments showed growth and expanded margins, GAAP operating margin was impacted by significant legal, separation, …

Solventum (NYSE: SOLV) raises 2026 guidance on strong Q2 earnings jump

Solventum (NYSE: SOLV) reported strong second-quarter 2026 results, with net sales of $2.2 billion and a 50.9% increase in adjusted diluted EPS to $2.55. The company also announced its intent to separate its Health Information Systems segment to focus on MedTech and raised its …

Solventum May Separate Software Used by More Than 75% of U.S. Hospitals

Solventum (NYSE: SOLV) announced its intent to separate its Health Information Systems (HIS) business, generating $1.4 billion in annual sales and serving over 75% of U.S. hospitals. This move is part of a three-phase transformation strategy aimed at optimizing its portfolio and maximizing shareholder …

Solventum under pressure to prove growth in earnings report By Investing.com

Solventum Corp. is under pressure to demonstrate organic growth in its upcoming second-quarter earnings report. Investors are keenly watching for sustained growth momentum across its segments, improved profitability, and how the company is managing pricing pressures, especially after outperforming expectations in its first quarter.

Solventum (NYSE:SOLV) Posts Better-Than-Expected Sales In Q2 CY2026

Solventum (NYSE:SOLV) reported better-than-expected Q2 CY2026 results, with sales up 2.2% year-on-year to $2.21 billion, beating analyst estimates. Its non-GAAP profit of $2.55 per share also significantly surpassed consensus estimates, leading management to raise its full-year Adjusted EPS guidance. Despite short-term revenue growth and …

Trading Systems Reacting to (SOLV) Volatility

The article discusses the volatility of Solventum Corporation (NASDAQ: SOLV) and presents AI-generated trading strategies. It highlights strong near and mid-term sentiment, potential for upside, and provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies. The analysis includes …

Solventum Corporation presenta sus resultados del segundo trimestre y del primer semestre de 2026

Solventum Corp (SOLV) (Q2 2026) Earnings Call Highlights: Strong Growth and Strategic ... By GuruFocus

Solventum Corp (SOLV) reported strong Q2 2026 results, exceeding expectations with significant organic growth across all segments and raised its full-year guidance. The company announced the separation of its Health Information Systems (HIS) business to focus on medtech and enhance shareholder value, while also …

Solventum outruns medical-supplies peers with a 9.5% week, yet volume has not fully endorsed the move

SOLV closed at 85.44 USD, within 3.6% of its 52-week high, with an active weekly trend but only 0.9x 13-week volume confirmation.

Solventum Corp. stock rises Monday, outperforms market

Solventum Corp. (SOLV) shares increased by 3.08% on Monday, closing at $88.07. This rise occurred during a generally positive trading session, where the S&P 500 Index gained 1.48% and the Dow Jones Industrial Average rose 1.32%, marking the end of a two-day losing streak …

Solventum to Report Q2 Earnings: What's in Store for the Stock?

Solventum (SOLV) is expected to report its second-quarter 2026 earnings on August 5th. Analysts project revenues of $2.17 billion and earnings of $1.91 per share, driven by strength in its MedSurg, Dental, and Health Information Systems segments, as well as the Acera acquisition and …

Solvar's 12% Fully Franked Yield and Special-Dividend Firepower: Is This Small-Cap Lender Australia's Hidden Income Machine?

Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer

Solventum (NYSE:SOLV) has appointed Neil Zieselman as its new Senior Vice President, Controller, and Chief Accounting Officer, succeeding Mary Wilcox. Zieselman brings extensive experience from several major corporations, and his appointment is expected to influence the company's financial controls and reporting practices. Investors are …

Sigma Solve net profit surges 143% in Q1FY27 on margin expansion

Solventum Corporation Revenue Breakdown – NYSE:SOLV

Solventum Corp. stock falls Friday, underperforms market

Solventum Corp. (SOLV) stock fell 1.59% on Friday, closing at $85.44, and underperformed the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average rise. This marks the second consecutive day of losses for Solventum.

Solventum Number of Employees 2026 | Employee Count & Headcount Data

Solventum Corp. (SOLV) had approximately 20,286 employees worldwide as of March 2026, marking a 367.6% growth since 2023. The company is actively hiring, with 874 active job postings in 2026, and its workforce is concentrated in the United States, Germany, and Poland. The average …

Sigma Solve net profit surges 142% in Q1FY26 to ₹1,257 lakh

Sigma Solve consolidated net profit rises 142.86% in the June 2026 quarter

SOLV|Solventum Corp|Price:85.140|Chg%:-1.680

This article provides a comprehensive stock analysis of Solventum Corp (SOLV) by TradingKey. It highlights that Solventum Corp's fundamentals are stable, with high growth potential and a fairly valued assessment within its industry. The analysis also covers institutional ownership, analyst ratings, and various financial …

KSolves Consolidated June 2026 Net Sales at Rs 41.44 crore, up 10.03% Y-o-Y

Solvay SA (SLVYY) Q2 2026 Earnings Call Highlights: Navigating Challenges and Strategic Positioning

This article first appeared on GuruFocus. Revenue: Underlying net sales in Q2 slightly over EUR1 billion, down 7% year-on-year. EBITDA: Underlying EBITDA of EUR187 million, down 20%, with an EBITDA margin of 18.1%. Free Cash Flow: Negative EUR11 million in Q2; EUR15 million for …

Solventum Corp stock hits 52-week high at 88.21 USD

Solventum Corp's stock has reached a 52-week high of $88.21, reflecting positive investor sentiment and a 20.57% increase over the past year. The healthcare technology firm, with a market capitalization of $14.92 billion, reported strong Q1 2026 earnings, surpassing expectations, and received an Outperform …

SOLN5759814 Bond Profile — Key Metrics

This article provides key metrics for the Solventum Corporation bond, SOLN5759814, which has a 5.45% coupon rate and matures on March 13, 2031. The bond was issued on February 27, 2024, with an outstanding amount of $1.21 million. Solventum Corp. operates as a healthcare …

Solvay second quarter 2026 results

Solvay S.A. Press release Regulated information published on July 29, 2026, at 7:00 a.m. CEST Full year guidance confirmed Highlights Underlying net sales in Q2 2026 reached €1,031 million, down -7.4% organically versus Q2 2025, reflecting continued weakness in soda ash pricing (particularly in …

Why is Solventum stock surging today?

Solventum stock surged over 7% today after UBS upgraded the healthcare company from Neutral to Buy, setting a price target of $95. This upgrade, combined with supportive analyst sentiment and an upcoming Q2 2026 earnings report on August 5, pushed Solventum shares towards their …

Solventum Corp (SOLV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Solventum Corp (SOLV), noting its current valuation score of 9.03, which ranks it 48th in the Healthcare Equipment & Supplies industry. The company's P/E ratio is 10.48, significantly below its recent high but above its recent low. …

SOLVENTUM CORP : UBS ASSUMES COVERAGE WITH BUY VS NEUTRAL RATING; TARGET PRICE $95 VS $78

UBS has initiated coverage of Solventum Corp (SOLV.N) with a "Buy" rating, upgrading it from a "Neutral" rating. The firm has also increased its target price for Solventum to $95 from the previous $78. This reflects a positive outlook on the company's stock performance.